Neogenomics Inc (NEO): Oort Douglas M Van , Chairman and CEO of Neogenomics Inc sold 481,387 shares on May 26, 2016. The Insider selling transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were sold at $8.72 per share for a total value of $4,202,403.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 20, 2016, Steven A Ross (CIO) sold 18,000 shares at $8.50 per share price.On May 3, 2016, Steven C Jones (Executive VP of Finance) sold 177,745 shares at $8.21 per share price.Also, On Mar 14, 2016, George Cardoza (Chief Financial Officer) sold 32,000 shares at $6.83 per share price.On Mar 10, 2016, Oort Douglas M Van (Chairman and CEO) sold 450,000 shares at $7.06 per share price.
Shares of NeoGenomics (NEO) ended Wednesday, May 25, 2016 session in red amid volatile trading. The shares closed down -0.22 points or -2.48% at $8.65 with 7,51,559 shares getting traded. Post opening the session at $8.85, the shares hit an intraday low of $8.64 and an intraday high of $8.89 and the price vacillated in this range throughout the day. The company has a market cap of $667 M and the number of outstanding shares has been calculated to be 7,71,17,678 shares. The 52-week high of NeoGenomics is $8.99 and the 52-week low is $5.05.
Company has been under the radar of several Street Analysts.NeoGenomics is Reiterated by The Benchmark Company to Buy and the brokerage firm has raised the Price Target to $ 9 from a previous price target of $8 .The Rating was issued on Apr 28, 2016.NeoGenomics is Initiated by The Benchmark Company to Buy and the brokerage firm has set the Price Target at $8. The Rating was issued on Mar 11, 2016.
NeoGenomics Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services which includes Cytogenetics testing which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues. and molecular testing which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA) as well as the structure and function of genes at a molecular level.